Leman Biotech and the team led by professor Xingbing Wang, Director of the First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), reached a clinical trial cooperation agreement on "Clinical Trial Study on the Safety and Efficacy of Metabolism-enhanced CD19 CAR-T Cell Injection in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma". The two parties have formally signed a cooperation agreement to establish a clinical project partnership and jointly promote multi-center IIT clinical research of metabolism-enhanced CAR-T cell therapy.

On December 9-10, 2022, Professor Chen Li, Vice President of the Shenzhen Institute of Advanced Technology and Director of the Key Laboratory of Quantitative Engineering Biology at the Chinese Academy of Sciences, led a delegation to visit the Swiss Federal Institute of Technology (EPFL), where the core technology of Leman Biotech was developed.

Leman Biotech was among the top 150 in the 2022 Venture50 Sprout List by Zero2IPO Ventures (1945. HK).

On November 15, 2022, Dr. Dudu Tong, R&D Director of Leman Biotech, was invited to participate in the "20+8 Industrial Cluster Exchange of Science and Technology Innovation Enterprises" held at the 2022 China High-Tech Fair by Shenzhen Angel FOF.

On November 14-15, 2022, Dr. Yugang Guo, co-founder of Leman Biotech, was invited to participate in the 2022 World Science and Technology Youth Forum and the launch ceremony of the Global-Asia-Pacific Region's "35 Under 35 Science and Technology Innovation" by MIT Technology Review.

In an interview with the Greater Geneva Bern area (GGBa) Invest Western Switzerland, Professor Li Tang, co-founder of Leman Biotech ......

From August to September 2022, Dr. Yugang Guo, co-founder of Leman Biotech, and his team members  ......

Leman Biotech and the team led by Professor Huang He from the First Affiliated Hospital of Zhejiang University School of Medicine have entered into a clinical trial collaboration agreement on the safety and efficacy of the metabolism-enhanced CD19 CAR-T cell injection (Meta10-19 CAR-T) in treating relapsed or refractory diffuse large B-cell lymphoma.